TerminatedPhase 2ACTRN12605000452695

Adoptive immunotherapy for the prevention of Human Cytomegalovirus (HCMV) reactivation and disease after Allogenic Stem Cell Transplantation

A phase I/II study to evaluate the effect of a single dose of human Cytomegalovirus (HCMV)-specific bulk cytotoxic T lymphocytes (CTL) to prevent complications associated with HCMV reactivation following allogeneic stem cell transplantation

Sponsor

Queensland Institute of Medical Research (QIMR)

Enrollment

15 participants

Start Date

Jun 30, 2002

Study Type

Interventional

Conditions

Human Cytomegalovirus (HCMV) reactivation and disease after Allogenic Stem Cell Transplantation

Summary

Since the inception of human organ transplantation, HCMV remains single most-important cause of infectious morbidity and mortality in immunocompromised transplant patients. This project is designed to develop immunotherapeutic strategies based on adoptve transfer of virus-specific killer T cells for the treatment of HCMV infection in transplant patients.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests whether giving patients immune cells from their stem cell donor can prevent cytomegalovirus (CMV) from reactivating after a stem cell transplant. Both men and women who are CMV-positive and receiving a stem cell transplant may be eligible. Participation involves receiving immune cell infusions and regular blood monitoring.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Donor-expanded bulk HCMV-specific CTL at a single dose on four occasions at monthly intervals, then monthly for 1 year.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000452695